Application No.: 09/687,864

Docket No.: 30906/41457UTL Response to Office Action Dated 9/20/05

Amendments to the Claims

1-14. Canceled

15. (Currently amended) An antigenic polypeptide comprising an antigen domain and a receptor-binding domain, said antigen domain comprising HIV-1 gp160 or a portion thereof and said receptor-binding domain comprising a CD40-binding polypeptide,

wherein the CD40-binding polypeptide is selected from the group consisting of CD154, extracellular domains of CD154 or a portion of the extracellular domain which retains the ability to bind CD40, anti-CD40 scFv, and single antibody variable regions that bind CD40.

- 16. (Previously presented) An antigenic polypeptide of claim 15, wherein said receptor-binding domain comprises at least a portion of an immunoglobulin.
- 17. (Previously presented) An antigenic polypeptide of claim 15, wherein said receptor-binding domain comprises a single chain Fv.
- 18. (Previously presented) An antigenic polypeptide of claim 15, wherein said CD-40 binding protein comprises CD 154 or a portion of CD 154.
- 19. (Previously presented) An antigenic polypeptide of claim 15, comprising an amino acid sequence according to any one of SEQ ID NO: 20, 21, 22, 23, 24, 25, 26, or 27.
- 20. (Previously presented) An antigenic polypeptide of claim 15, wherein said CD40binding polypeptide comprises a camelid immunoglobulin variable region.
- 21. (Currently Amended) An antigenic polypeptide of claim 15, wherein said receptor-binding domain is capable of binding CD40 and one or more additional receptors.

22. (Canceled)

23. (Previously presented) An antigenic polypeptide of claim 15, encoded by a polynucleotide comprising a sequence according to any one of SEQ ID NO: 12, 13, 14, 15, 16, 17, 18, or 19.

Application No.: 09/687,864

Response to Office Action Dated 9/20/05

24. (Previously presented) An antigenic polypeptide of claim 23, wherein said polynucleotide is operably linked to a DNA plasmid.

Docket No.: 30906/41457UTL

25. (Canceled)

- 26. (Previously presented) An antigenic polypeptide of claim 15 that is capable of eliciting an immune response in an animal.
- 27. (Previously presented) An antigenic polypeptide of claim 15 that is produced in an animal.
- 28. (Previously presented) An antigenic polypeptide comprising an antigen domain and a receptor-binding domain, said antigen domain comprising HIV-1 gp160 or a portion of HIV-1 gp160, said receptor-binding domain comprising at least a portion of a CD 154 polypeptide capable of binding to CD40.
- 29. (Previously presented) An antigenic polypeptide of claim 28 encoded by a polynucleotide comprising a sequence according to any one of SEQ ID NO: 12, 13, 14, 15, 16, 17, 18, or 19.
- 30. (Previously presented) An antigenic polypeptide of claim 28 wherein said antigenic polypeptide comprises an amino acid sequence according to any one of SEQ ID NO: 20, 21, 22, 23, 24, 25, 26, or 27.

31-33. (Canceled)